Isabelle Laure Ray-Coquard

Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial

Isabelle Laure Ray-Coquard, Julien Dômont, Emmanuelle Tresch‐Bruneel et al. · Journal of Clinical Oncology · 2015 · 191 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · Journal of Clinical Oncology · 2018 · 74 citations

Medicine, Oncology, Pharmacotherapy +13

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

Sana Intidhar Labidi‐Galy, Manuel Rodrigues, José Luís Sandoval et al. · Annals of Oncology · 2022 · 71 citations · Full text

Medicine, Oncology, Pharmacology +14

Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers

Nicolas Penel, Jean‐Michel Coindre, Antoine Giraud et al. · Cancer · 2017 · 65 citations · Full text

Medicine, Oncology, Pathology +16

LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

Éric Pujade-Lauraine, Frédèric Selle, Giovanni Scambia et al. · Annals of Oncology · 2021 · 56 citations

Medicine, Gynecology, Oncology +15